Neurology

MS prognosis – 30-year follow-up

 

A 30-year follow-up of patients with clinically isolated syndrome (CIS) reports that MRI findings (lesion location, lesion number) at baseline and at one year were the most robust prognostic factors of long-term outcomes (Chung et al. Ann Neurol 2020;87:63-74). Results at 20 years were previously published as Fisniku et al. Brain 2008;131:808-817.

Read More

TOPICS:

Targeting amyloid in AD – optimism amid controversy

 

The year 2019 had its share of disappointing drug trials in Alzheimer disease, leading many to question whether anti-amyloid therapies were the optimal strategy. But that view may have shifted with controversial developments later in the year. Read More

TOPICS:

Sequencing MS therapies – a changing landscape

 

Comment by Dr. Virender Bhan – Senior neurologist, Burnaby/Vancouver, BC, Canada.

NeuroSens recently posted a survey on sequencing disease-modifying therapies (DMTs) in multiple sclerosis to investigate whether clinicians’ approaches have changed in the past 2-3 years. The current survey was a follow-up to a series of surveys conducted over a one-year period ending in December 2017 that accompanied an 8-part article on sequencing. (For a summary of those results see Are opinions changing on changing therapies in MS?, NeuroSens, October 22, 2019). Read More

TOPICS:

Sequencing MS therapies – a changing landscape

 

Comment by Dr. Virender Bhan – Senior neurologist, Burnaby/Vancouver, BC, Canada.

NeuroSens recently posted a survey on sequencing disease-modifying therapies (DMTs) in multiple sclerosis to investigate whether clinicians’ approaches have changed in the past 2-3 years. The current survey was a follow-up to a series of surveys conducted over a one-year period ending in December 2017 that accompanied an 8-part article on sequencing. (For a summary of those results see Are opinions changing on changing therapies in MS?, NeuroSens, October 22, 2019). Read More

TOPICS: